Medicare Enrolled
Dr. David Lin, DO
Internal Medicine · Rosemead, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Lin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lin
Dr. David Lin is an internal medicine specialist in Rosemead, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Lin performed 12,105 Medicare services across 4,511 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lin received a total of $26,470 from 62 pharmaceutical and/or device companies across 845 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in internal medicine. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 2% volume in CA
$26,470 industry payments
Medicare Practice Summary
Medicare Utilization ↗12,105
Medicare services
Top 2% in CA for internal medicine
4,511
Unique beneficiaries
$76
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~637 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
3,459 | $68 | $111 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,187 | $101 | $140 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,982 | $79 | $120 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
1,184 | $65 | $116 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
441 | $89 | $125 |
| Annual alcohol misuse screening, 5 to 15 minutes | 440 | $21 | $40 |
| Annual intensive behavioral therapy for cardiovascular disease, 15 minutes A yearly, in-person session focused on intensive behavioral therapy to help manage cardiovascular disease. The session lasts for 15 minutes and is conducted with the patient individually. |
440 | $28 | $40 |
| Annual depression screening | 406 | $21 | $40 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
400 | $144 | $180 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
266 | $148 | $225 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 241 | $20 | $50 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
241 | $25 | $25 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
171 | $157 | $225 |
| Nursing facility visit, moderate complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves moderate medical decision making and takes at least 30 minutes. |
100 | $92 | $123 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
95 | $124 | $225 |
| Annual wellness visit, initial visit A yearly appointment to review your health and create a personalized prevention plan. This initial visit focuses on preventive care and health assessment. |
28 | $183 | $220 |
| Smoking cessation counseling, more than 10 minutes Intensive counseling session focused on helping patients quit smoking and tobacco use, lasting more than 10 minutes. |
24 | $30 | $40 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$26,470
Total received (2018-2024)
Avg $3,781/year across 7 years
Top 5% in CA for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
62
Companies
845
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$26,137 (98.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$332 (1.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,630
2023
$4,896
2022
$3,356
2021
$3,131
2020
$1,773
2019
$4,930
2018
$3,754
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$957
GlaxoSmithKline, LLC.
$445
Amgen Inc.
$426
Phathom Pharmaceuticals, Inc.
$360
Boehringer Ingelheim Pharmaceuticals, Inc.
$280
Eisai Inc.
$249
AIMMUNE THERAPEUTICS, INC.
$182
Teva Pharmaceuticals USA, Inc.
$182
UCB, Inc.
$163
Bayer Healthcare Pharmaceuticals Inc.
$161
PFIZER INC.
$157
Ardelyx, Inc.
$152
Lilly USA, LLC
$150
Esperion Therapeutics, Inc.
$125
VIVUS LLC
$120
ABBVIE INC.
$107
Novo Nordisk Inc
$88
IRONWOOD PHARMACEUTICALS, INC
$85
Neurocrine Biosciences, Inc.
$64
Almatica Pharma LLC
$47
Otsuka America Pharmaceutical, Inc.
$33
Dexcom, Inc.
$27
Philips North America LLC
$21
Mylan Specialty L.P.
$19
RedHill Biopharma Inc.
$17
Lundbeck LLC
$13
Top 3 companies account for 39.5% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$2,898
Amarin Pharma Inc.
$2,732
Amgen Inc.
$2,538
Novo Nordisk Inc
$1,416
GlaxoSmithKline, LLC.
$1,387
AbbVie, Inc.
$1,357
Janssen Pharmaceuticals, Inc
$1,253
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,251
Teva Pharmaceuticals USA, Inc.
$922
PFIZER INC.
$869
ABBVIE INC.
$704
Bayer HealthCare Pharmaceuticals Inc.
$624
Radius Health, Inc.
$611
Astellas Pharma US Inc
$511
Lilly USA, LLC
$432
Novartis Pharmaceuticals Corporation
$414
Bayer Healthcare Pharmaceuticals Inc.
$397
AbbVie Inc.
$381
Phathom Pharmaceuticals, Inc.
$360
Allergan, Inc.
$316
Neurocrine Biosciences, Inc.
$306
Eisai Inc.
$284
Merck Sharp & Dohme Corporation
$280
VIVUS LLC
$262
Lexicon Pharmaceuticals, Inc.
$240
CMP Pharma, Inc.
$237
Gilead Sciences, Inc.
$236
CeQur Corporation
$233
Avanir Pharmaceuticals, Inc.
$227
Otsuka America Pharmaceutical, Inc.
$216
Allergan Inc.
$192
AIMMUNE THERAPEUTICS, INC.
$182
UCB, Inc.
$163
RedHill Biopharma Inc.
$156
Ardelyx, Inc.
$152
Kowa Pharmaceuticals America, Inc.
$144
Dexcom, Inc.
$126
Esperion Therapeutics, Inc.
$125
Takeda Pharmaceuticals U.S.A., Inc.
$120
UROVANT SCIENCES INC
$114
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$111
Almatica Pharma LLC
$96
Corium, LLC
$94
SK Life Science, Inc.
$91
E.R. Squibb & Sons, L.L.C.
$87
IRONWOOD PHARMACEUTICALS, INC
$85
Nestle HealthCare Nutrition Inc.
$79
Alkermes, Inc.
$68
Acorda Therapeutics, Inc
$65
Sumitomo Pharma America, Inc.
$55
EISAI INC.
$54
Sunovion Pharmaceuticals Inc.
$33
LINUS HEALTH, INC.
$30
Merck Sharp & Dohme LLC
$23
Philips North America LLC
$21
Xeris Pharmaceuticals, Inc.
$19
Mylan Specialty L.P.
$19
Abbott Laboratories
$16
Biogen, Inc.
$16
Lundbeck LLC
$13
Ironwood Pharmaceuticals, Inc
$13
ACADIA Pharmaceuticals Inc
$13
Top 3 companies account for 30.9% of all-time payments
Associated products mentioned in payments ›
(AK6) Vest Therapy · ABILIFY MYCITE · ADLARITY · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · ARISTADA · AUSTEDO · Adlarity · Aimovig · Amitiza · Austedo XR · BELSOMRA · BREZTRI · BRILINTA · BYSTOLIC · Briviact · CHANTIX · COLOGUARD · COLOGUARD DNA CAPTURE REAGENTS · CORE COGNITIVE EVALUATION · CREON · CeQur Simplicity · Creon · DEXCOM G7 GSS (161) · Dayvigo · Dexcom G6 Transmitter · Dexilant · ELIQUIS · ENTRESTO · EUCRISA · EVENITY · FARXIGA · Fycompa · GEMTESA · GVOKE PFS · IBSRELA · INBRIJA · INGREZZA · INVEGA SUSTENNA · INVOKANA · Infinity DBS Pulse Generators · Inpefa · JANUVIA · JARDIANCE · Kerendia · LEQVIO · LINZESS · LOREEV XR · LYBALVI · LYRICA · Leqembi · Linzess · Livalo · MOUNJARO · MYRBETRIQ · NEXLIZET · NUEDEXTA · NUPLAZID · Norliqva · Nuedexta · ONGENTYS · Ongentys · Otezla · Ozempic · PANCREAZE · PAXLOVID · PREVNAR - 13 · PREVNAR 13 · Prolia · REXULTI · RYBELSUS · Repatha · Rybelsus · SHINGRIX · STIOLTO RESPIMAT · SYMBICORT · Seglentis · TRADJENTA · TRELEGY ELLIPTA · TRULANCE · TRULICITY · Talicia · Tresiba · Tymlos · UBRELVY · Uloric · Utibron · VIBERZI · VOQUEZNA · VRAYLAR · Vascepa · Vemlidy · Victoza · XARELTO · XIFAXAN · YUPELRI · ZENPEP
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 5% for internal medicine in CA.
Geographic Context
Internal medicine physicians within 10 mi
5,425
Per 100K population
55.1
County median income
$87,760
Nearest hospital
BHC ALHAMBRA HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Lin is a clinical cardiology specialist, with above-average Medicare volume (top 2% in CA), with low-engagement industry engagement in the top 5% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Lin experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Lin performed 3,459 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lin receive payments from pharmaceutical companies?
Yes. Dr. Lin received a total of $26,470 from 62 companies across 845 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lin's costs compare to other internal medicine physicians in Rosemead?
Dr. Lin's average Medicare payment per service is $76. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in Rosemead
Browse internal medicine physicians in Rosemead ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in CA
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in CA
Which CA internal medicine physicians receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Amarin Pharma Inc. Payments to Doctors
See all physicians who received payments from Amarin Pharma Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology